ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0911

Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis

Iris Navarro-Millan1, Mackenzie Brown2, Yuliana Domínguez Páez3, Geyanne Lui4, Joan Weiner1, Shelley fritz1, Tien Sydnor-Campbell5, Aberdeen Allen6, Assem Jabri1, Shilpa Venkatachalam7, Kelly Gavigan8, William Benjamin Nowell9, Jeffrey Curtis10, Liana Fraenkel11 and Monika Safford1, 1Weill Cornell Medicine, New York, NY, 2Weill Cornell Medicine, Brooklyn, NY, 3Weill Cornell Medicine, Bronx, NY, 4Albert Einstein College of Medicine, New York, NY, 5Weill Cornell Medicine, Philedelphia, 6Weill Cornell Medicine, Parlin, 7Global Healthy Living Foundation, New York, NY, 8Global Healthy Living Foundation, Upper Nyack, NY, 9Global Healthy Living Foundation, Nyack, NY, 10University of Alabama at Birmingham, Hoover, AL, 11Berkshire Medical Center, Lenox, MA

Meeting: ACR Convergence 2022

Keywords: clinical trial, education, patient, prevention, rheumatoid arthritis, risk assessment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 13, 2022

Title: RA – Diagnosis, Manifestations, and Outcomes Poster II

Session Type: Poster Session B

Session Time: 9:00AM-10:30AM

Background/Purpose: Only 37% of patients with rheumatoid arthritis (RA) receive screening for cardiovascular disease (CVD) despite their high risk. To improve CVD prevention, we designed the CArdiovascular Risk assEssment for patients with Rheumatoid Arthritis (CARE RA) intervention. It consists of patient education alongside the assistance of a peer coach. A peer coach is a person with RA that has been trained to coach another person with RA to request a CVD risk assessment from their rheumatologist. The goal of this abstract is to present the preliminary results for this intervention.

Methods: This is a randomized controlled trial for patients with RA. We included patients with RA between 40-75 years of age, no history of CVD, and no cholesterol test or CVD risk assessment in the past 2 years. We excluded people with diabetes or already on lipid lowering therapy (LLT). Participants were randomized to either CARE RA or a control group. CARE RA participants completed 4 weekly calls with a peer coach right before their rheumatologist appointment, to coach their client on requesting CVD risk from their rheumatologist, and one call the week after their appointment to discuss steps to follow once the intervention was completed. The calls followed a curriculum on RA and CVD, that included strategies to lower the risk for CVD and the importance of a CVD risk assessment. The control arm completed the same curriculum but without the assistance of a peer coach. The primary outcome was the number of participants who received a CVD risk assessment defined as, having a cholesterol test, discussing the results of a cholesterol test with their rheumatologist, or initiating LLT if indicated. Data was collected at baseline (5 weeks prior to the rheumatologist appointment), 1-week, and 3-months after the appointment. Differences between arms were determined at 1-week and 3-months after the rheumatologist appointment.

Results: There were 60 participants (Figure 1); 4 dropped out from CARE RA and 4 from the control arm; mean age was 57, 90% females, 80% white (Table 1). At 1-week, 22 participants in CARE RA versus 18 in the control arm received a CVD risk assessment. At 3-month, all participants that completed CARE RA had a CVD risk assessment (Figure 2; p=0.62) and 5 initiated LLT. No participant in the control arm initiated LLT.

Conclusion: The CARE RA intervention seems feasible by means of participants completing the intervention with the peer coaches. Preliminarily, CARE RA seems promote CVD risk assessment, but a larger sample is needed to obtain definitive results about its effectiveness.

Supporting image 1

Figure 1. Flow diagram of the patients screened and recruited in the pilot of the CARE RA intervention

Supporting image 2

Table 1. Baseline Demographics for Participants Enrolled in the CARE RA Program

Supporting image 3

Figure 2. Number of Participants with Cholesterol Test or LLT Initiation at 1-Week and 3-Month After Completion of CARE RA


Disclosures: I. Navarro-Millan, Sweden Orphan Biovitrum (SOBI); M. Brown, None; Y. Domínguez Páez, None; G. Lui, None; J. Weiner, None; S. fritz, None; T. Sydnor-Campbell, None; A. Allen, None; A. Jabri, None; S. Venkatachalam, None; K. Gavigan, None; W. Nowell, Global Healthy Living Foundation, AbbVie Inc., Amgen, Eli Lilly; J. Curtis, AbbVie/Abbott, Amgen, ArthritisPower, Aqtual, Bendcare, Bristol-Myers Squibb(BMS), CorEvitas, FASTER, GlaxoSmithKlein(GSK), IlluminationHealth, Janssen, Labcorp, Eli Lilly, Myriad, Novartis, Pfizer, Sanofi, Scipher, Setpoint, UCB, United Rheumatology; L. Fraenkel, None; M. Safford, None.

To cite this abstract in AMA style:

Navarro-Millan I, Brown M, Domínguez Páez Y, Lui G, Weiner J, fritz S, Sydnor-Campbell T, Allen A, Jabri A, Venkatachalam S, Gavigan K, Nowell W, Curtis J, Fraenkel L, Safford M. Peer Coach Intervention to Improve Primary Cardiovascular Disease Screening for Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/peer-coach-intervention-to-improve-primary-cardiovascular-disease-screening-for-patients-with-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/peer-coach-intervention-to-improve-primary-cardiovascular-disease-screening-for-patients-with-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology